Role of Tirzepatide in Managing Type 2 Diabetes

Introduction to Tirzepatide

Tirzepatide is a highly effective dual GIP/GLP-1 receptor agonist that should be prioritized in type 2 diabetes treatment due to its superior glycemic control, exceptional weight loss benefits, and favorable cardiometabolic profile compared to other diabetes medications, as recommended by the American Diabetes Association 1, 2

Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes management, providing a unique mechanism of action 3, 4

The American Diabetes Association recommends considering tirzepatide as a preferred agent when both glycemic control and weight management are treatment goals, due to its superior efficacy and safety profile 1, 2
Tirzepatide is particularly valuable for patients with A1C ≥1.5% above individualized glycemic goals who may require more potent glucose-lowering therapy, as stated in the 2024 ADA Standards of Care 2
Offers additional benefits over insulin and sulfonylureas, specifically lower risk for hypoglycemia and favorable weight outcomes, making it a preferred option for patients with type 2 diabetes 1

The American Diabetes Association suggests evaluating patient's current glycemic control, weight status, and presence of cardiovascular risk factors when initiating tirzepatide therapy 1, 5
Prioritize tirzepatide for patients with inadequate glycemic control on current therapy, overweight or obesity where weight loss is a treatment goal, and need for potent glucose-lowering without increased hypoglycemia risk 2, 5, 6
Assess glycemic response, weight changes, and tolerability at regular intervals, and screen for malnutrition in patients experiencing significant weight loss (>20%) 1, 6

For patients with severely uncontrolled diabetes, tirzepatide can be an effective alternative to insulin initiation, as recommended by the American Diabetes Association 1
Tirzepatide should be continued beyond reaching weight loss goals to maintain health benefits, and consider screening for malnutrition and sarcopenia in patients experiencing significant weight loss 6, 7